FIND DOCTORS
|
Name: Hong,Xiaonan |
| Education & Professional Experience |
Shanghai Medical University GCP Center N/A 1998.03 GCP Training Shanghai Second Medical University M.D. 1976 Clinical Medicine |
|
| Specialty |
Since 2006 Director Doctor, department of Medical Oncology Cancer Hospital Fudan University 1996-2006 Vice Director Doctor, department of Medical Oncology Cancer Hospital Fudan University 1986-1988 Visiting Scholar, Karmanos Cancer Institute, USA 1996-1997 Visiting Scholar of NCIC Epidemiology Unit, University of Toronto, Canada Vice Superintendents of Medical Oncology Cancer Hospital Fudan University Chief of Multidisciplinary combined treatment group of malignant lymphoma Member of the Standing Committee Branch of Chemotherapy, China Anti-Cancer Association Commissioner, Branch of Cancer, Shanghai Medical Association Commissioner, Branch of Clinical Epidemiology, Shanghai Medical Association Executive Board Member, Shanghai Anti-Cancer Association Associate Editor of Modern Clinical Oncology Writer of Chapter Chemotherapy in Practice Internal Medicine Writer of Chapter Chemotherapy in Practice Surgical Medicine |
|
| Research |
2006-2010: A Randomized, open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subject with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B- Cell Non-hodgkin’s Lymphoma. Since 2008: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant Since 2009: A Phase 3 Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin 2009-2010 Avastin/placebo Combined with R-CHOP for Previously Untreated Diffuse Large B-Cell Lymphoma 2009-2011 R-ICE for Relapsed/Refractory Diffuse Large B-Cell Lymphoma 2010-2011 Bortezomib Combined with R-CAP for Previously Untreated Mantle Cell Lymphoma 2009-2011 C225+PF for Advanced head and neck squamous cell carcinoma |
|
| Awards | Obtain the Shanghai science progress rewards | |
| Out-patient Schedule |
Wed |
|
